Significant Phase III Results With CIMZIA(TM) In Rheumatoid Arthritis - Radiographic Data Demonstrated Significant Reduction In Joint Damage

Fri, 23 Feb 2007 08:00 PM EST

... UCB today announced key results of a pivotal Phase III study (RAPID 1) involving nearly 1,000 patients on CIMZIA(TM) (certolizumab pegol), the first PEGylated, Fc-free anti-TNF, intended for the treatment of moderate to severe rheumatoid arthritis (RA). [click link for full article] ...